Immunoglobulin Replacement Therapy Market Trends

Growth Drivers

• Growing Prevalence of CIDP and PIDs Globally - The global market for IgG replacement therapy is expanding quickly as a result of the increasing prevalence of bleeding disorders and CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) in patients. Also, the growing number of people with autoimmune diseases and other pathological problems is driving up demand for IgG replacement therapy solutions. According to a recent study, some of the more than 80 distinct autoimmune illnesses that impact about 4% of the global population are type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and scleroderma. Moreover, the growing incidences of PIDs globally are also propelling the market growth. Many of these immune system abnormalities are brought on by issues with the genetic code, which serves as a blueprint for creating the body's cells (DNA). Primary immunodeficiency illnesses come in over 300 different forms, and the list keeps growing as new ones are found by researchers.

• Increased Utilization of Immunoglobulin Replacement Therapy in Kawasaki Illness - The market is expected to increase commercially due to the rising incidence of Kawasaki illness in children and the increasing need for immunoglobulin replacement therapy as a treatment. Over the coming years, there will likely be more usage of steroids to treat Kawasaki sickness because they are the only therapeutic alternative available (except for immunoglobulin replacement therapy), which has considerable side effects. Furthermore, the demand for immunoglobulin replacement therapy is expected to rise due to factors like elevated patient awareness and a rise in the occurrence of illnesses with insufficient antibody supplies, which will propel the market.
• Increased Launches of Innovative Therapies by the Key Manufacturers - The growing amount of FDA approvals could be a major factor in this industry's growth. For instance, in January 2022, Octapharma declared that a broader spectrum of patients with acquired immune deficiencies now have more flexible treatment options with the expansion of the indication for cutaquig®, a human immunoglobulin for subcutaneous administration, in the European Union (EU). Adults, children, and adolescents with severe or recurring infections, inadequate antimicrobial therapy, and either proven specific antibody failure or a serum immunoglobulin (IgG) level below 4 g/L are included in the expanded cutaquig® prescription. Consequently, several domestic and foreign companies are investing in the IgG replacement therapy market.

Challenges

• Severe Side Effects of the Therapy – Approximately 25% of people may experience adverse effects when taking their medicine. They are not dangerous; however, they are usually bothersome or mild.  Headache, fever, chills, exhaustion, sore muscles or joints, and allergic responses are a few typical adverse effects. Usually, these symptoms are transient and mild. More severe side effects, such as allergic reactions, kidney issues, and blood clots, are uncommon but possible. Therefore, the severe side effects of the therapy may hinder the growth of the immunoglobulin (IgG) replacement therapy market.
• Inaccessibility to Some Patients due to the High Costs of the Therapy may Hamper the Market Growth
• Limited Availability of Immunoglobulin Products may Impede the Market Growth